Compare Amplify Cybersecurity ETF (HACK) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Repligen Corporation Common Stock — how do they compare? Amplify Cybersecurity ETF trades at $122 (market cap $3.56B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.1× Amplify Cybersecurity ETF's market cap, and Amplify Cybersecurity ETF is more actively traded (331,197 versus 1,259,263). Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 27 Days and Repligen Corporation Common Stock for 0 Days on average.
| HACK | RGEN | |
|---|---|---|
Market Cap | $3.56B | $11.14B |
Volume | 331,197 | 1,259,263 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $194.57 |
52-Week Low | $70.69 | $102.87 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $127.09, down 0.12% on the day, but maintains a bullish technical stance with moving averages signaling strength and momentum indicators like ADX showing strong trend confirmation. The ETF recently hit a 52-week high, driven by AI safety concerns and rising cybersecurity demand, though short interest has surged significantly, indicating mixed sentiment. Financial ratios are not applicable as this is an ETF tracking a basket of cybersecurity stocks.
The outlook for HACK is supported by structural growth in cybersecurity spending, particularly from AI-driven threats, but faces risks from elevated short interest and potential sector rotation. Upside depends on continued sector outperformance, while downside risks include profit-taking after strong gains and broader tech volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
